Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
In addition to generating antibodies, Mojsov needed to devise a chromatographic method to detect GLP-1 (7-37) and separate it from other relevant peptides (Barany, Barany)
Thats why they used Serena Williams to show that even an athlete who isnt overweight uses it
Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
The research was not especially glamorous
The company cannot claim compliance with FDA requirements as a defense when other regulatory agencies deemed warnings necessary, and the WHO issued global safety alerts